Download
s00432-021-03827-9.pdf 1,25MB
WeightNameValue
1000 Titel
  • Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies
1000 Autor/in
  1. Odinius, Timo O. |
  2. Buschhorn, Lars |
  3. Wagner, Celina |
  4. Hauch, Richard T. |
  5. Dill, Veronika |
  6. Dechant, Marta |
  7. Buck, Michele C. |
  8. Shoumariyeh, Khalid |
  9. Moog, Philipp |
  10. Schwaab, Juliana |
  11. Reiter, Andreas |
  12. Brockow, Knut |
  13. Götze, Katharina |
  14. Bassermann, Florian |
  15. Höckendorf, Ulrike |
  16. Branca, Caterina |
  17. Jost, Philipp J. |
  18. Jilg, Stefanie |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-10-15
1000 Erschienen in
1000 Quellenangabe
  • 148(2):331-340
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-021-03827-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800915/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Hypereosinophilia represents a heterogenous group of severe medical conditions characterized by elevated numbers of eosinophil granulocytes in peripheral blood, bone marrow or tissue. Treatment options for hypereosinophilia remain limited despite recent approaches including IL-5-targeted monoclonal antibodies and tyrosine kinase inhibitors.!##!Methods!#!To understand aberrant survival patterns and options for pharmacologic intervention, we characterized BCL-2-regulated apoptosis signaling by testing for BCL-2 family expression levels as well as pharmacologic inhibition using primary patient samples from diverse subtypes of hypereosinophilia (hypereosinophilic syndrome n = 18, chronic eosinophilic leukemia not otherwise specified n = 9, lymphocyte-variant hypereosinophilia n = 2, myeloproliferative neoplasm with eosinophilia n = 2, eosinophilic granulomatosis with polyangiitis n = 11, reactive eosinophilia n = 3).!##!Results!#!Contrary to published literature, we found no difference in the levels of the lncRNA Morrbid and its target BIM. Yet, we identified a near complete loss of expression of pro-apoptotic PUMA as well as a reduction in anti-apoptotic BCL-2. Accordingly, BCL-2 inhibition using venetoclax failed to achieve cell death induction in eosinophil granulocytes and bone marrow mononuclear cells from patients with hypereosinophilia. In contrast, MCL1 inhibition using S63845 specifically decreased the viability of bone marrow progenitor cells in patients with hypereosinophilia. In patients diagnosed with Chronic Eosinophilic Leukemia (CEL-NOS) or Myeloid and Lymphatic Neoplasia with hypereosinophilia (MLN-Eo) repression of survival was specifically powerful.!##!Conclusion!#!Our study shows that MCL1 inhibition might be a promising therapeutic option for hypereosinophilia patients specifically for CEL-NOS and MLN-Eo.
1000 Sacherschließung
lokal Eosinophilia/pathology [MeSH]
lokal Thiophenes/therapeutic use [MeSH]
lokal Hypereosinophilic Syndrome/pathology [MeSH]
lokal Antibodies, Monoclonal/therapeutic use [MeSH]
lokal Hypereosinophilic Syndrome/therapy [MeSH]
lokal Eosinophils/metabolism [MeSH]
lokal MCL1
lokal Sulfonamides/therapeutic use [MeSH]
lokal Hypereosinophilia
lokal Bridged Bicyclo Compounds, Heterocyclic/therapeutic use [MeSH]
lokal Granulomatosis with Polyangiitis/therapy [MeSH]
lokal EGPA
lokal Venetoclax
lokal Case-Control Studies [MeSH]
lokal Granulomatosis with Polyangiitis/genetics [MeSH]
lokal Hypereosinophilic syndrome
lokal Myeloproliferative Disorders/pathology [MeSH]
lokal Proto-Oncogene Proteins c-bcl-2/genetics [MeSH]
lokal Myeloproliferative Disorders/genetics [MeSH]
lokal Granulomatosis with Polyangiitis/pathology [MeSH]
lokal Bcl-2-Like Protein 11/physiology [MeSH]
lokal Eosinophilia/genetics [MeSH]
lokal Original Article – Cancer Research
lokal BH3-mimetics
lokal Humans [MeSH]
lokal Hypereosinophilic Syndrome/genetics [MeSH]
lokal Apoptosis
lokal Eosinophilia/mortality [MeSH]
lokal Pyrimidines/therapeutic use [MeSH]
lokal Proto-Oncogene Proteins c-bcl-2/metabolism [MeSH]
lokal CEL-NOS
lokal HL-60 Cells [MeSH]
lokal Hypereosinophilic Syndrome/mortality [MeSH]
lokal Myeloproliferative Disorders/therapy [MeSH]
lokal Eosinophilia/therapy [MeSH]
lokal Antineoplastic Agents/therapeutic use [MeSH]
lokal Cells, Cultured [MeSH]
lokal S63845
lokal Eosinophils/pathology [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/T2Rpbml1cywgVGltbyBPLg==|https://frl.publisso.de/adhoc/uri/QnVzY2hob3JuLCBMYXJz|https://frl.publisso.de/adhoc/uri/V2FnbmVyLCBDZWxpbmE=|https://frl.publisso.de/adhoc/uri/SGF1Y2gsIFJpY2hhcmQgVC4=|https://frl.publisso.de/adhoc/uri/RGlsbCwgVmVyb25pa2E=|https://frl.publisso.de/adhoc/uri/RGVjaGFudCwgTWFydGE=|https://frl.publisso.de/adhoc/uri/QnVjaywgTWljaGVsZSBDLg==|https://frl.publisso.de/adhoc/uri/U2hvdW1hcml5ZWgsIEtoYWxpZA==|https://frl.publisso.de/adhoc/uri/TW9vZywgUGhpbGlwcA==|https://frl.publisso.de/adhoc/uri/U2Nod2FhYiwgSnVsaWFuYQ==|https://frl.publisso.de/adhoc/uri/UmVpdGVyLCBBbmRyZWFz|https://frl.publisso.de/adhoc/uri/QnJvY2tvdywgS251dA==|https://frl.publisso.de/adhoc/uri/R8O2dHplLCBLYXRoYXJpbmE=|https://frl.publisso.de/adhoc/uri/QmFzc2VybWFubiwgRmxvcmlhbg==|https://frl.publisso.de/adhoc/uri/SMO2Y2tlbmRvcmYsIFVscmlrZQ==|https://frl.publisso.de/adhoc/uri/QnJhbmNhLCBDYXRlcmluYQ==|https://frl.publisso.de/adhoc/uri/Sm9zdCwgUGhpbGlwcCBKLg==|https://orcid.org/0000-0003-1774-7605
1000 Hinweis
  • DeepGreen-ID: 7dd3e519c1774d5f917b76ae580237aa ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6446896.rdf
1000 Erstellt am 2023-04-28T14:30:22.601+0200
1000 Erstellt von 322
1000 beschreibt frl:6446896
1000 Zuletzt bearbeitet 2023-10-20T19:13:08.007+0200
1000 Objekt bearb. Fri Oct 20 19:13:08 CEST 2023
1000 Vgl. frl:6446896
1000 Oai Id
  1. oai:frl.publisso.de:frl:6446896 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source